http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 발행기관 : YEAR Wolters Kluwer Health, Inc. All rights reserv (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Antithrombotic activity of Vitis labrusca extract on rat platelet aggregation
Kwon, Se-Uk,Lee, Hoon-Yeon,Xin, Mingjie,Ji, Su-Jeong,Cho, Hyoung-Kwon,Kim, Dae-Sung,Kim, Dae-Ki,Lee, Young-Mi YEAR Wolters Kluwer Health, Inc. All rights reserv 2016 Blood coagulation & fibrinolysis Vol.27 No.2
<P>Vitis labrusca is a grapevine that has antioxidant, neuroprotective, hepatoprotective, and anticarcinogenic activity. However, the antithrombotic effect of Vitis labrusca leaves on platelets is yet to be ascertained. We investigated the inhibitory effect of V. labrusca leaf extract (VLE) on platelet aggregation in vitro and ex vivo. The thromboxane B-2 (TXB2) and serotonin concentrations were measured by ELISA. The flavonoids content was measured by ultraperformance liquid chromatography (UPLC). The antithrombotic activity of VLE was evaluated using various agonists in vitro. VLE strongly inhibited adenosine diphosphate (ADP)-induced platelet aggregation. In rats, VLE treatment (100mg/kg) reduced ADP-stimulated platelet aggregation, without affecting tail bleeding and coagulation time. Moreover, VLE significantly suppressed TXB2 and serotonin secretion. UPLC analysis indicated that VLE contains quercetin, isorhamnetin, and rutin. Our results indicate that VLE possesses antiplatelet activity via the suppression of TXB2 and serotonin, without affecting bleeding. Further, we identified the flavonoids present in VLE. Thus, VLE may be a potential agent for the prevention of cardiovascular diseases. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.</P>
-
Moon, Ae Ran,Choi, Dong-Hyun,Jahng, Su-Young,Kim, Bo-Bae,Seo, Hong-Joo,Kim, Sang Hun,Ryu, Sang-Wan,Song, Heesang,Kim, Tae-Hyoung YEAR Wolters Kluwer Health, Inc. All rights reserv 2016 Blood coagulation & fibrinolysis Vol.27 No.1
<P>This study was designed to establish the relationship of high-sensitivity C-reactive protein (hsCRP) and mean platelet volume (MPV) with the development of adverse outcomes after percutaneous coronary intervention (PCI). hsCRP levels and MPV were analysed in 372 patients who underwent PCI, with the primary endpoint as major adverse cardiac and cerebrovascular events (MACCE): a composite of cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), ischemic stroke and stent thrombosis. During the follow-up period (mean, 25.8 months), there were 21 cardiac deaths, 10 MIs including four stent thrombosis events, seven ischemic strokes and 29 TVRs. The hsCRP cut-off level was set at 0.31mg/dl using the receiver operating characteristic curve to differentiate between the groups with and without MACCE. The MPV cut-off level was set at 8.00fl by the receiver operating characteristic curve to differentiate between the groups with and without MACCE. A Kaplan-Meier analysis revealed that the high hsCRP group (0.31mg/dl) had a significantly higher cardiac death and MACCE rate than the low hsCRP group (<0.31mg/dl), and the high MPV group (>8.00fl) had a significantly higher cardiac death and MACCE rate than the low MPV group (8.00fl). Furthermore, the high hsCRP and MPV groups were significantly associated with an increased risk of MACCE. These results show that hsCRP and MPV are predictive markers after PCI for MACCE; they are also additively associated with a higher risk of MACCE. Blood Coagul Fibrinolysis 27: 70-76 Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.</P>
-
Lee, Nuri,Kim, Ji-Eun,Gu, Ja-Yoon,Yoo, Hyun Ju,Kim, Inho,Yoon, Sung-Soo,Park, Seonyang,Han, Kyou-Sup,Kim, Hyun Kyung YEAR Wolters Kluwer Health, Inc. All rights reserv 2016 Blood coagulation & fibrinolysis Vol.27 No.1
<P>Disseminated intravascular coagulation (DIC) is characterized by consumption of coagulation factors and anticoagulants. Thrombin generation assay (TGA) gives useful information about global hemostatic status. We developed a new TGA system that anticoagulant addition can deplete thrombin generation in plasma, which may reflect defective anticoagulant system in DIC. TGAs were measured on the calibrated automated thrombogram with and without thrombomodulin or protein Z in 152 patients who were suspected of having DIC, yielding four parameters including lag time, endogenous thrombin potential, peak thrombin and time-to-peak in each experiment. Nonsurvivors showed significantly prolonged lag time and time-to-peak in TGA-protein Z system, which was performed with added protein Z. In multivariate Cox regression analysis, lag time and time-to-peak in TGA system were significant independent prognostic factors. In TGA-protein Z system, lag time and time-to-peak were revealed as independent prognostic factors of DIC. Protein Z addition could potentiate its anticoagulant effect in DIC with poor prognosis, suggesting the presence of defective protein Z system. The prolonged lag time and time-to-peak in both TGA and TGA-protein Z systems are expected to be used as independent prognostic factors of DIC. Blood Coagul Fibrinolysis 27: 84-89 Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.</P>
-
Clinical characteristics of pulmonary embolism with concomitant pneumonia
Cha, Seung-Ick,Choi, Keum-Ju,Shin, Kyung-Min,Lim, Jae-Kwang,Yoo, Seung-Soo,Lee, Jaehee,Lee, Shin-Yup,Kim, Chang-Ho,Park, Jae-Yong YEAR Wolters Kluwer Health, Inc. All rights reserv 2016 Blood coagulation & fibrinolysis Vol.27 No.3
<P>Although pneumonia is associated with an increased risk of venous thromboembolism, patients with pulmonary embolism and concomitant pneumonia are uncommon. The aim of the present study was to investigate the clinical features of pulmonary embolism with coexisting pneumonia. We retrospectively compared clinical, radiologic and laboratory parameters between patients with pulmonary embolism and concomitant pneumonia (pneumonia group) and those with unprovoked pulmonary embolism (unprovoked group), and then between the pneumonia group and those with pulmonary infarction (infarction group). Of 794 patients with pulmonary embolism, 36 (5%) had coexisting pneumonia and six (1%) had no provoking factor other than pneumonia. Stroke was significantly more common in the pneumonia group, than either the unprovoked group or the infarction group. In the pneumonia group, fever was significantly more common and serum C-reactive protein levels were significantly higher. By contrast, central pulmonary embolism and right ventricular dilation on computed tomography were significantly less frequent in the pneumonia group. In addition, an adverse outcome due to pulmonary embolism was less common in the pneumonia group than in either of the other two groups. The coexistence of pulmonary embolism and pneumonia is rarely encountered in clinical practice, especially without the presence of other factors that could provoke venous thromboembolism and is commonly associated with stroke. It is characterized by lower incidences of central pulmonary embolism and right ventricular dilation and by a lower rate of adverse outcomes due to pulmonary embolism itself.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
